08:46:33 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriBioteknik
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.

Kalender

2022-09-21 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020
2022-05-13 13:30:00
OSLO/LONDON, 13 May 2022: EXACT Therapeutics AS ("EXACT-Tx" or "the Company")
Euronext Growth: EXTX), a clinical stage biopharmaceutical company with a
mission to enhance the therapeutic efficacy of medicines through
ultrasound-mediated drug delivery, today announces that its new Chief Executive
Officer ("CEO") Per Walday will start 6 June 2022.

As announced by the Company on 28th March 2022, Per, who worked alongside the
Founders and some of the Board Members of EXACT-Tx during his time as Global
Head of Project Management at GE Healthcare, is joining EXACT-Tx as CEO. During
his time at GE Healthcare, he was responsible for all development programs of
new pharmaceutical products which included R&D efforts within the field of
ultrasound and microbubbles which paved the way for what would become years
later EXACT-Tx' Acoustic Cluster Therapy (ACT®). Per was most recently CEO of
PCI Biotech (OSE: PCIB) with a technology involving a drug-device combination
developed for use in the field oncology. The experience and wealth of knowledge
that he has acquired in those fields will be of enormous help to the success of
ACT®.

Dr Masha Strømme, Executive Board Chair, commented: "The Board and I look
forward to working with Per. His intimate knowledge of ultrasound along with
therapeutic expertise and strong leadership will lead the Company through the
next phase of its development."

Dr Per Walday, Chief Executive Officer-designate of EXACT-Tx, said: "Remarkable
innovation and progress have been made with the ACT® platform since I led the
development of related ultrasound technology initially aimed for diagnostic use
in GE Healthcare. I am very excited to be joining EXACT- Tx in June and aim to
further maximise the value of the innovative ACT® platform for ultrasound
mediated drug enhancement and accelerate our journey towards becoming a leading
precision health company."

As a result of Per's appointment, some of the activities of EXACT-Tx will be
relocated to Oslo. Dominic Moreland will be stepping down as Chief Financial
Officer ("CFO"). Dominic has a three month notice period and he will work in
the transition period with Ole Fegth who will then assume the role of interim
CFO. The Board of EXACT-Tx thanks Dominic for his contribution.

END
For more information, please contact:

Masha Strømme, Executive Chair of the Board of Exact Therapeutics AS
Exact-Therapeutics email: Masha@EXACT-tx.com

Dominic Moreland, CFO
EXACT Therapeutics Email: Dominic@EXACT-tx.com

About Exact-Therapeutics AS
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® is a unique approach to ultrasound-mediated, targeted drug enhancement -
with the potential to significantly amplify the clinical utility of a wide range
of therapeutic agents across a multitude of indications including within
oncology (chemotherapy, immunotherapy), infectious diseases, and neurological
conditions.

Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause Actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.